ALLERGIC RHINITIS TREATMENT MARKET ANALYSIS

Market Size and Trends

The global allergic rhinitis treatment market is estimated to be valued at USD 16.10 Bn in 2024 and is expected to reach USD 22.43 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.8% from 2024 to 2031.

To learn more about this report, request a free sample copy

The growing pollution levels across major cities due to rapid urbanization and industrialization have led to increased instances of allergies and other diseases. Furthermore, the rising patient awareness regarding the availability of various treatment options for allergic rhinitis is also contributing to the market growth. However, the presence of alternative treatment options and expiry of patents of blockbuster drugs may hamper the market growth. Overall, increasing environmental pollution and growing health consciousness among consumers are expected to drive the global allergic rhinitis treatment market growth during the forecast period.

Increasing Availability of Allergen Immunotherapy Solutions

The increasing availability of allergen immunotherapy solutions is one of the factors that is expected to drive the market growth during the forecast period. For instance, in June 2021, Stallergenes Greer, one of the global leaders in allergy immunotherapy, announced that the Alusta, subcutaneous allergen immunotherapy (SCIT) solution for different allergies involving rhinitis, conjunctivitis, rhino conjunctivitis, or asthma is now available in Spain and Italy.

Market Concentration and Competitive Landscape

To learn more about this report, request a free sample copy

Growing industrialization and urbanization have led to higher concentrations of outdoor allergens like pollen, mold, dust, and animal dander in the air. At the same time, people are spending more time indoors where indoor allergens from furnishings, cleaning products, and other materials are present. This has increased individual's exposure and susceptibility to develop allergic rhinitis. Thus, the increasing prevalence of allergic rhinitis boosts the demand for effective treatment which is expected to drive the market growth over the forecast period. For instance, according to the World Allergy Organization report in October 2020, over 400 million people suffer from allergic rhinitis around the world, which to a large extent remains underdiagnosed and undertreated. In the U.S., it affects between 10-30% of the adult general population and up to 40% of children, making it the fifth most common chronic disease.

To learn more about this report, request a free sample copy

The major factors that are expected to hinder growth of the global allergic rhinitis treatment market include the termination of the clinical trial study. For instance, in November 2022, a clinical trial of Tree MATA MPL or Tree MATA immunotherapy for allergic rhinitis and type I hypersensitivity I was terminated due to poor enrollment of subjects. The clinical trial was sponsored by Allergy Therapeutics, a manufacturer of subcutaneous and sublingual immunotherapy treatments.

Market Opportunities – Increasing Launch of Awareness Campaigns

Increasing adoption of inorganic growth strategies such launch of awareness campaigns by key market players is expected to offer lucrative growth opportunities in the market. For instance, in June 2023, Alkem, a global pharmaceutical company, announced that they had launched "Stop Sneeze to Wheeze" Campaign to Raise Awareness on Allergic Rhinitis and Asthma Coexistence during World Allergy Week 2023. The programme highlights the idea of "One Airway, One Disease" and seeks to increase awareness of the coexistence of allergic rhinitis and asthma.

To learn more about this report, request a free sample copy

The treatment type segment includes immunotherapy, anti-histamines, decongestants, leukotriene receptor antagonists, corticosteroids, and others. The immunotherapy sub-segment is estimated to hold 30.7% of the market share in 2024 owing to its targeted approach in addressing the root cause of allergic rhinitis. Immunotherapy, also known as desensitization or hypo-sensitization, counteracts the allergic reaction that an individual suffers due to allergens such as pollen, dust mites, and animal dander. Unlike symptomatic treatments like antihistamines that only offer relief from the symptoms, immunotherapy aims to reduce sensitivity to allergens over time and provide long lasting relief. It works by exposing the patient to gradually increasing doses of the allergen(s) that cause their symptoms, in order to induce tolerance. This 'tolerance induction' affords the individual protection against future reactions upon re-exposure to these allergens. As a consequence, patients may find long term reduction or elimination of symptoms on immunotherapy. Its targeted mechanism catering to the cause rather than the symptoms alone has made it the treatment of choice for individuals seeking a long-term solution to their allergic rhinitis.

Insights, By Route of Administration: Various Benefits of Oral Administration Over Other Modes

The route of administration segment includes oral, nasal, intraocular, and others. The oral sub-segment is estimated to hold 44.1% of the market share in 2024 due to the various benefits of oral administration over other modes. Oral medication is the most convenient route for self-administration as tablets or capsules can be taken without needing assistance. This makes adherence to treatment simpler. Additionally, oral drugs typically have higher bioavailability compared to other modes meaning higher amounts of the drug reach the target sites in the body resulting in better efficacy. The avoidance of repeated invasions of the nasal or other mucosa seen with other administration modes also adds to patient comfort with oral drugs. Furthermore, oral drugs usually have lower production and distribution costs compared to other complex drug delivery systems. Together, the convenience, effectiveness, and lower costs associated with the oral route have cemented its status as the preferred administration method for allergic rhinitis treatment.

Insights, By Distribution Channel: Hospital pharmacies control higher market share due to the specialized services offered

The distribution channel segment includes hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies sub-segment is estimated to hold 57.8% of the market share in 2024 owing to the specialized services they provide. As healthcare experts, hospital pharmacists are well-versed in allergy management and able to offer specialized guidance to patients. They ensure each patient receives tailor-made treatment best suited to their condition and lifestyle. Patients regularly visiting hospitals also benefit from continuity of care as all their treatment needs can be addressed under one roof. Hospital pharmacies also stock a wider range of medications including specialty drugs for complex cases. This enables more comprehensive management of allergic rhinitis. The oversight of hospital staff further helps address any drug-related issues timeously. The specialized know-how and integrated services preferentially drive customers to hospital pharmacies over other channels for their allergic rhinitis treatment needs.

Regional Insights

To learn more about this report, request a free sample copy

North America remains the dominant region in the global allergic rhinitis treatment market and is estimated to hold 37.4% of the market share in 2024 owing to its developed healthcare infrastructure and strong presence of leading pharmaceutical manufacturers in the U.S. With awareness among consumers regarding allergy diagnosis and management being fairly high, there is a considerable demand for prescription and over-the-counter medication options across major countries in the region. Furthermore, the presence of several well-established contract research organizations (CROs) and research universities encourages clinical trials for new drug formulations.

Asia Pacific is poised to be the fastest growing region owing to rising environmental pollution levels and changing lifestyle patterns in densely populated nations like India and China. This has significantly increased the prevalence of allergic reactions among general population. At the same time, improving access to private and public healthcare along with increasing spending on specialty medicines is fueling market revenue growth. While pricing of branded drugs remains relatively high in the region compared to generics, industry players are actively focusing on affordable product offerings to tap rising demand from the massive patient pool. Partnerships with local pharmaceutical companies have also enabled global vendors to strengthen supply chain and distribution networks across emerging Asia Pacific countries.

Market Report Scope

Key Developments

• In May 2023, Altamira Therapeutics Ltd., a global healthcare company, announced positive top-line results from the randomized controlled NASAR clinical trial evaluating its Bentrio nasal spray in patients with seasonal allergic rhinitis (SAR). Bentrio nasal spray is formulated as a drug-free and preservative-free gel emulsion designed to help protect against airborne allergens such as pollen or house dust mites.
• In August 2022, Hikma Pharmaceuticals PLC, a pharmaceutical company, announced the launch of RYALTRIS (olopatadine hydrochloride and mometasone furoate nasal spray) in the US. RYALTRIS is approved by the US Food and Drug Administration (FDA) for the treatment of symptoms of seasonal allergic rhinitis (SAR) in adult and pediatric patients 12 years of age and older
• In June 2021, through a procedure known as a partial prescription to non-prescription transition, the U.S. Food and Drug Administration (FDA) approved a nasal antihistamine for non-prescription use. The US FDA approved Astepro (azelastine hydrochloride nasal spray, 0.15%) for seasonal and perennial allergic rhinitis, commonly known as allergies for adults and children six years of age and older
• In November 2021, Revolo Biotherapeutics, a biotherapeutics company, started a phase II clinical trial for IRL201104, a novel immunomodulatory peptide drug indicated for seasonal allergic rhinitis.
• In March 2021, ALK-Abelló A/S, a pharmaceutical company, announced its submission of a registration application in China, under National Medical Products Administration (NMPA), Chinese agency for regulating drugs and medical devices, for its ACARIZAX, a house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet

*Definition: Allergic rhinitis also called as hay fever, is an inflammation of the inside of the nose due to an allergic reaction to tiny particles in the air called allergens. Allergic rhinitis is also called cold-like symptoms because the symptoms resemble to cold symptoms such as sneezing, itchiness, blocked or runny nose, etc. The immune system reacts to a particular type of allergen, which causes allergic rhinitis. This reaction releases a different number of chemicals inside of mucous membrane of the nose due to which the nose becomes swollen and forms an excessive amount of mucus. Various allergens that cause allergic rhinitis include pollen, spores, house dust mites, flakes of skin, or droplets of saliva or urine from a certain animal. When allergic rhinitis is caused by pollen, it is called hay fever.

Market Segmentation

•  Treatment Type Insights (Revenue, USD Bn, 2019 - 2031)
  • Immunotherapy 
    • Sub-cutaneous Immunotherapy (SCIT)
    • Sub-lingual Immunotherapy (SLIT)
  • Anti-histamines
  • Decongestants
  • Leukotriene Receptor Antagonists
  • Corticosteroids
  • Others
•  Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
  • Oral
  • Nasal
  • Intraocular
  • Others
•  Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-commerce
• Regional Insights (Revenue, USD Bn, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Merck & Co., Inc.
  • Boehringer Ingelheim International GmbH
  • AstraZeneca
  • GSK plc.
  • Johnson & Johnson Services, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Mylan N.V.
  • Aytu BioPharma, Inc.
  • Regeneron Pharmaceuticals Inc.
  • Revolo Biotherapeutics
  • Dr. Reddy’s Laboratories Ltd
  • Glenmark Pharmaceuticals Ltd